VIGANO', OTTAVIA
VIGANO', OTTAVIA
Universita' degli Studi di MILANO
Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19
2022 A. d'Arminio Monforte, T. Alessandro, D.B. Sara, F. Bai, C. Tincati, L. Gazzola, O. Vigano', M. Allegrini, D. Mondatore, D. Tesoro, D. Barbanotti, G. Mule', R. Castoldi, D.B. Anna, B. Teresa, D.A. Chiumello, S. Centanni, P. Sabrina, N.V. Orfeo, G.C. Marchetti, C. Alessandro
Three case reports of West Nile virus neuroinvasive disease: lessons from real-life clinical practice
2021 C. Falcinella, M. Allegrini, L. Gazzola, G. Mule, D. Tomasoni, O. Vigano, A. d'Arminio Monforte, G. Marchetti, C. Tincati
Female gender is associated with long COVID syndrome : a prospective cohort study
2021 F. Bai, D. Tomasoni, C. Falcinella, D. Barbanotti, R. Castoldi, G. Mule', M. Augello, D. Mondatore, M. Allegrini, A. Cona, D. Tesoro, G. Tagliaferri, O. Vigano', E. Suardi, C. Tincati, T. Beringheli, B. Varisco, C.L. Battistini, K. Piscopo, E. Vegni, A. Tavelli, S. Terzoni, G. Marchetti, A. D'Arminio Monforte
Haemoptysis and fever in a young refugee from Somalia
2018 M. Mondoni, O. Viganò, M. Ferrarese, M. Bimbatti, M. Cavallini, L. Codecasa, A. D'Arminio Monforte, G. Bulfamante, S. Centanni, G. Sotgiu
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients : a randomized, controlled, pilot study (the REYAGEN study)
2015 S. Bonora, S. Rusconi, A. Calcagno, M. Bracchi, O. Viganò, J. Cusato, M. Lanzafame, A. Trentalange, L. Marinaro, M. Siccardi, A. D'Avolio, M. Galli, G. Di Perri
Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients
2014 S. Bonora, A. Calcagno, O. Vigano, P. Bigliano, L. Marinaro, E. Colella, G. Orofino, L. Trentini, M.C. Tettoni, A. D'Avolio, S. Mercadante, M. Galli, G.D. Perri, S. Rusconi
Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatmentefficacy in UGT1A1*28 polymorphism carriers
2012 L. Ferraris, O. Viganò, A.M. Peri, M. Tarkowski, G. Milani, S. Bonora, F. Adorni, C. Gervasoni, E.G.I. Clementi, G. Di Perri, M. Galli, A. Riva
Predictive factors of therapeutic success of a HAART regimen including atazanavir with or without ritonavir in HIV-infected patients
2012 A. Giacomelli, M. Franzetti, B. Vergani, L. Oreni, M. Morosi, V. Di Cristo, E. Colella, O. Viganò, M. Galli, S. Rusconi
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV : experience in a pediatric population
2012 S. Rusconi, V. Giacomet, C. Mameli, A. Viganò, O. Viganò, F. Adorni, M. Galli, G.V. Zuccotti
Does GSS Still Maintain Relevance on HAART Outcome After the Introduction of Newest Active Antiretroviral Drugs? 48 Weeks Results
2011 M. Ortu, P. Vitiello, F. Adorni, R. Rossotti, P. Di Vincenzo, O. Viganò, M. Galli, S. Rusconi
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens
2011 D. Gonzalez de Requena, S. Bonora, O. Viganò, A. Calcagno, C. Cometto, A. D'Avolio, L. Baietto, V. Ghisetti, S. Magnani, S. Ferramosca, P. Vitiello, M. Galli, S. Rusconi, G. Di Perri
New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses
2009 S. Rusconi, M. Lo Cicero, O. Viganò, F. Sirianni, E. Bulgheroni, S. Ferramosca, A. Bencini, A. Bianchi, L. Ruiz, C. Cabrera, J. Martinez-Picado, C.T. Supuran, M. Galli
Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an HIV-infected patient failing all four classes of antiretroviral drugs
2008 A. Di Biagio, B. Bruzzone, R. Rosso, O. Vigano', G. Icardi, C. Viscoli, S. Rusconi
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir
2008 B. Vergani, M. Lo Cicero, O. Viganò, F. Sirianni, S. Ferramosca, P. Vitiello, P. Di Vincenzo, M.P. De Pasquale, M. Galli, S. Rusconi
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation
2007 C. Gervasoni, O. Vigano, E. Gianelli, M. Ortu, M. Galli, S. Rusconi
New HIV protease inhibitors for drug-resistant viruses
2006 S. Rusconi, O. Viganò
Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral- experienced HIV-1-infected subjects treated with tenofovir combination therapy [2]
2005 M. Lo Cicero, E. Bulgheroni, F. Soster, O. Viganò, P. Cicconi, M. Galli, S. Rusconi
Unusual codon 69 insertions : influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility
2004 E. Bulgheroni, F. Croce, P. Citterio, O. Viganò, R. Visonà, E. Sala, M. Galli, S. Rusconi
Analysis of protease inhibitor combinations in vitro : activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates
2004 E. Bulgheroni, P. Citterio, F. Croce, M. Lo Cicero, O. Viganò, F. Soster, T.C. Chou, M. Galli, S. Rusconi
Resolution of multidrug-refractory oesophageal candidiasis in an AIDS patient after treatment with caspofungin
2002 S. Sollima, M. Corbellino, P. Cicconi, M. Piazza, O. Vigano', S. Antinori